Valuation
- Market cap
- —
- Revenue TTM
- —
- Net income TTM
- —
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 7,800
- Avg volume
- —
- Day's range
- $0.64 – $0.64
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of mon...
Show more
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 46 86 79 72 10
- Website
- https://www.egetis.com
- Address
- Klara Norra Kyrkogata 26, Stockholm, Sweden
Latest news
No headlines yet.
